On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Subsidiaries Work to Secure New Deals for DehydraTECH in Various Industries

Company: Lexaria Bioscience Corp. (LXRP)
Category: Stock Spotlights

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is finding success through its ability to form subsidiaries specializing in the use of its patented drug-delivery platform, DehydraTECH. A recent article discussing the company reads, “DehydraTECH is a drug-delivery platform patented for cannabidiol and all other nonpsychoactive cannabinoids, as well as THC (tetrahydrocannabinol) and psychoactive cannabinoids. The technology is an enabling platform that works across multiple industries, thereby providing a large base of consumers with healthier forms of consumption than lighting up. . . . LXRP and DehydraTECH stand out among the competition. The company has a total of 10 patents issued with more than 50 patents pending worldwide. Few companies within the cannabis industry have attracted the attention of Fortune 500-type corporations, and even fewer are inking deals on their own terms. Lexaria Bioscience is one such standout.”

To view the full article, visit http://cnw.fm/Lr1st

About Lexaria Bioscience Corp.

Lexaria Bioscience has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and quicker onset of lipophilic active molecules. Lexaria has 10 patents granted in the United States and Australia, and has filed over 50 patent applications worldwide across 10 patent families. Lexaria’s technology provides more rapid delivery to the bloodstream, as well as important taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Contact us: 303.498.7722